Cardiovascular diseases (CVD) represent a major health issue in patients with schizophrenia and bipolar disorder (BD). While many studies have shown increased CVD risks in schizophrenia and BD, the underlying mechanisms remain unclear. Psychiatric medications such as anti-psychotics and various mood stabilizers are associated with metabolic syndrome and CVD. Yet metabolic abnormalities have been reported in drug-naïve patients, leading to our hypothesis that the two types of disorders may share a common genetic basis. Using a polygenic risk score (PRS) approach, we investigated the associations of schizophrenia and BD with a comprehensive panel of cardiometabolic traits. Effect sizes of individual variants were based on large-scale meta-analyses of genome-wide association studies (GWAS). We performed two kinds of analyses, one based on paired summary statistics results and the other based on the Northern Finland Birth Cohort, a GWAS sample with measurement of metabolic traits. We found strong evidence of genetic predisposition to glucose metabolism abnormalities, type 2 diabetes and coronary artery disease in both schizophrenia and BD patients. On the other hand, we observed an inverse relationship between PRS of body mass index (BMI) and both schizophrenia and BD. However, schizophrenia was associated with higher polygenic scores of waist-hip ratio, especially after controlling for BMI. Taken together, these results suggested shared genetic bases among cardiometabolic traits with schizophrenia and BD.
Introduction

Background
Increased rates of cardiovascular diseases (CVD) have become a major area of concern for patients with schizophrenia or bipolar affective disorders 1, 2 . People with schizophrenia have a life expectancy around 15 to 20 years shorter than the average population while the life expectancy for bipolar patients is 10 to 15 years shorter 3 . The mortality ratio in schizophrenia and bipolar patients is about 2.5 to 3-fold as compared to the general population 4 . Deaths from cardiovascular diseases have been proposed as a major contributor to the increased mortality 1, 5 . Osborn et al. 6 reported a 3-fold increase in CVD mortality in patients with severe mental illness (schizophrenia-spectrum or bipolar disorders) aged 18-49 and a 2-fold increase in patients aged 50-75.
The metabolic syndrome is a key risk factor for cardiovascular morbidity and mortality. It represents a cluster of metabolic abnormalities including dyslipidemia, impaired glucose tolerance, insulin resistance, hypertension and central obesity 7 .
A raised prevalence of metabolic syndrome has been observed in schizophrenia patients.
McEvoy et al. 8 reported that in the CATIE study, the baseline prevalence of metabolic syndrome was 35% and 50% in males and female patients respectively. Mitchell et al. 9 conducted a large-scale meta-analysis comprising 25962 subjects and reported that metabolic syndrome is found in almost 1 out of 3 unselected schizophrenia patients. For bipolar disorder, heightened risks of metabolic abnormalities have also been recognized. Vancampfort et al. 10 estimated in a meta-analysis that the overall rate of metabolic syndrome is 37.3%, which is significantly higher than the general population.
The underlying causes for increased risk of metabolic disorders are not completely 4 understood. It has been suggested that a variety of factors including tobacco smoking, physical inactivity, inadequate somatic health-care services, antipsychotic medications and underlying genetics may all contribute to the heightened metabolic risks 1 . In particular, anti-psychotic medications and mood stabilizers have been established as significant contributors to metabolic abnormalities 11, 12 .
Nevertheless, metabolic abnormalities have also been observed in schizophrenia patients who are drug-naïve. For example, drug-naïve patients were reported to show impaired glucose tolerance, raised fasting glucose levels and insulin resistance in several studies 13 . Impaired glucose tolerance has also been observed in first-degree relatives of affected patients 14 .
There is currently no clear evidence of other abnormalities such as hypertension, increased central obesity or dyslipidemia in drug-naïve patients. A thorough review of metabolic syndrome in drug-naïve and treated schizophrenia patients can be found in Chadda et al 13 .
Very few studies have investigated metabolic traits in drug-naïve bipolar patients and compared them to a control population. A recent study showed an increased rate of insulin resistance in these patients but there were no difference in the rate of metabolic syndrome 15 .
The previous studies on drug-naïve patients are usually of small sample size (mostly less than 100 subjects), and often included only a subset of metabolic parameters. In addition, it is difficult to test if the drug-naïve patients are more susceptibility to cardiovascular diseases such as diabetes and coronary artery disease, as the patients are usually at a young age and the number of cases is too small to achieve reasonable power.
Despite the limitations, studies in drug-naïve patients suggest a shared underlying pathophysiology of cardiometabolic traits with schizophrenia and bipolar disorder. As both 5 psychiatric and cardiometabolic traits are highly heritable 16, 17 , it is reasonable to suspect a shared genetic basis between them. In this study we investigated potential shared genetic predispositions by polygenic risk scores (PRS). PRS was first proposed by Purcell et al. 18 to study the polygenic basis of schizophrenia and its shared genetic basis with bipolar affective disorder. It has increasingly been used in recent years to a variety of complex diseases
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.
We made use of large-scale GWAS meta-analyses results for schizophrenia, BD and a comprehensive panel of metabolic and cardiovascular traits to construct polygenic scores. We employed the statistical approach in the R package gtx 20 for association testing, using pairs of summary results as input. We also examined PRS associations with cardiovascular risk factors in the Northern Finland Birth Cohort with individual genotype and phenotype data.
To our knowledge, this is the first systemic study on the shared genetic bases of cardiometabolic traits with both schizophrenia and BD using PRS. In a related work, Andreassen et al. 21 proposed a conditional false discovery rate approach to identify loci associated with both schizophrenia and CVD risk factors, with an aim to improving gene discovery in schizophrenia. In the current work we took a completely different statistical approach, and we also studied bipolar patients and a wider range of metabolic parameters and diseases. We also studied the directions of associations in this study which was not investigated in Andreassen et al. 21 .
Materials and methods
Derivation of polygenic risk scores (PRS)
PRS are derived from the summary statistics of GWAS meta-analyses, obtained from the The PRS is derived from a weighted sum of allelic counts, with the weights given by log odds ratios of individual genetic variants. The PRS for an individual i (r i ) can be denoted as
where ij x is the allelic count for the jth SNP for the ith individual, j w is the weight given to the jth SNP, given by the log odds ratio or regression coefficient in a linear regression. We employed two approaches for PRS testing. In the first approach, only the summary statistics of each pair of traits are used. Association testing was carried out by the method gtx described by Johnson 20 . This method was also described in a number of papers [29] [30] [31] . Briefly, we tested for the association of the PRS derived from the first trait with a second trait i y by regression:
Then it can be shown that the regression coefficient  can be estimated by Multiple testing was corrected by the false discovery rate (FDR) procedure, which controls for the expected proportion of false positives. The R program p.adjust was used to compute the corresponding FDR for every hypothesis test, which is also known as the q-value (the proportion of null was set to be 1 in all calculations). A q-value smaller than 0.05 is regarded as significant.
Results
Schizophrenia and cardiometabolic traits
The associations of schizophrenia with cardiometabolic traits using paired summary statistics are shown in Table 1 and Supplementary Tables 1 and 2 . Firstly PRS are constructed from metabolic traits and schizophrenia was treated as the outcome or target phenotype. Intuitively, PRS from the metabolic traits can be regarded as a proxy of the actual level of the trait. For instance, by studying the association of polygenic scores of FG with schizophrenia as the target phenotype, we are essentially testing for difference in a proxy measure of FG in schizophrenia 9 patients versus controls. For binary traits, the polygenic scores may be regarded as the underlying liability to the corresponding disorder.
The strongest associations were observed for CAD (p = 3.07E-97), DM (p = 5.45E-08) and BMI (p = 1.04E-11). Polygenic scores of CAD and DM are positively associated with schizophrenia, while an inverse association was observed for BMI. On the other hand, WHR showed a positive relationship with schizophrenia, and the result became more significant after controlling for BMI (p = 3.99E-05).
As for traits related to glucose metabolism, besides DM, fasting glucose showed the strongest association with schizophrenia (p = 0.00641), and insulin levels were also positively associated, but the significance was weaker (p = 0.0139). BMI adjustment slightly attenuated the results. As for lipid traits, lower polygenic scores of LDL, TC and TG and a higher polygenic score of HDL were associated with schizophrenia.
When polygenic score of schizophrenia was used as a predictor variable and metabolic traits as outcomes, the strongest associations were again seen for BMI, CAD and DM. Association results for HDL and WHR (adjusted for BMI) were also highly significant, while other traits showing mostly nominal or non-significant associations with q-values greater than 0.05.
For analyses on the Northern Finland Birth Cohort, the most significant association was WHR adjusted for BMI (p = 0.00542) ( Table 2 and Supplementary Tables 5 and 6 ). Other results were largely non-significant, probably owing to a much smaller sample size of NFBC compared to the GWAS meta-analyses. Table 3 and Supplementary Tables 3 and 4 showed the associations of BD with cardiometabolic traits using paired summary statistics. Similar to schizophrenia, the strongest associations were observed for BMI (p = 9.34E-13), CAD (p = 2.83E-23) and DM (p = (Table 4, Supplementary Tables 7 and 8 ).
Bipolar disorder and cardiometabolic traits
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Discussion
We have performed polygenic risk score studies on the possible shared genetic basis of schizophrenia and BD with a comprehensive panel of cardiometabolic traits. We discovered a number of significant associations, which we shall discuss in the following sections.
Schizophrenia and cardiometabolic traits
The most remarkable finding is the strong polygenic associations of schizophrenia with both DM and CAD. Raised cardiovascular morbidity and mortality is well-established in schizophrenia, yet it is difficult to disentangle the numerous possible underlying factors, including the side-effects of antipsychotics. We found that polygenic risks (or genetic liabilities)
of DM and CAD are associated with schizophrenia, and vice versa. Such a relationship has not 11 been discovered from studies of drug-naïve subjects, as the patients were usually young and the number of DM and CAD cases was too small to achieve statistical power. To our knowledge, this is also the first study to show a shared genetic basis of schizophrenia with coronary heart disease. In line with a genetic propensity to developing diabetes, we also observed higher polygenic scores of FG in schizophrenia. It is notable that multiple studies have found impaired glucose tolerance or insulin resistance in drug-naïve patients and their first-degree relatives 14, [35] [36] [37] [38] [39] [40] .
Despite increased cardiovascular risks in schizophrenia patients, surprisingly, we found evidence for an inverse relationship between polygenic scores of BMI and schizophrenia.
Interestingly, a population cohort study of over 1 million men in Sweden also reported that subjects with lower BMI had an increased risk of developing schizophrenia 41 . A similar study in Denmark reached the same conclusions 42 . A few studies in drug-naïve patients also revealed a trend of lower BMI. For instance, lower BMI among drug-free schizophrenia patients was reported by Spelman et al. 14 and Pandmavati et al. 43 . However, some studies failed to detect any differences in BMI between schizophrenia cases and controls 35, 36 . The underlying pathophysiology for an inverse relationship between BMI and schizophrenia is unknown. One hypothesis is that poor nutritional status, however subtle, may adversely affect neural development 41 which leads to psychotic disorders.
While we observe that lower BMI polygenic score is associated with schizophrenia and vice versa, we observed the opposite trend for WHR. Polygenic association of higher WHR with schizophrenia, especially after adjustment for BMI, is shown both in the Northern Finland cohort sample and analyses using summary statistics. Consistent with this finding, Ryan et al.
reported higher WHR and three times more intra-abdominal fat in drug-free schizophrenia patients compared to BMI-matched controls 44 . Thakore et al. 45 and Sengupta et al. 46 reported 12 increased WHR in drug-free patients compared to controls. While some studies did not find any differences in WHR 35, 47 , they were of small sample sizes and inadequate power may explain the inconsistent results. Waist-hip ratio reflects visceral fat deposition, and has been suggested to be an informative predictor of cardiovascular risks independent of BMI 48, 49 .
Excess visceral adiposity may partially explain the increased risks for DM and CAD despite a tendency of lower BMI. However it is also possible that some shared genetic factors may specifically increase the risks of DM and CAD without major effects on lipid levels, body weight or other known CV risk factors.
For lipid traits, we observed schizophrenia patients tend to have lower polygenic scores of LDL but higher HDL levels. It is possible that such relationships are related to lower BMI in schizophrenia subjects. However as BMI-adjusted GWAS meta-analyses for lipid traits are not available, we did not directly test this hypothesis in our analyses with summary statistics. We did not find associations with lipid levels in the NFBC sample. Two previous clinical studies on drug-naïve patients had found significantly lower TC and LDL 35, 37 , while others failed to find any associations.
Bipolar disorder and cardiometabolic traits
Similar to schizophrenia, we found that higher polygenic risks of CAD and DM are associated with BD, suggesting a shared genetic basis of BD with CAD or DM. To our knowledge, this is the first report on a polygenic overlap among the disorders. On the other hand, we observed an inverse genetic relationship between BMI and BD. One previous clinical study reported a higher prevalence of being overweight among bipolar patients 50 . However, the weight measurements were not made during euthymic period and 71.4% of the patients were depressed during the measurement. It is possible that the symptoms of bipolar depression contributed to the findings. As remarked by the authors, their findings might be more related to 13 the current episode of illness than to the underlying disorder 50 . Given that schizophrenia and BD are highly genetically correlated 16 , it may not be surprising that a similar inverse relationship exists between polygenic scores of BMI and BD. While WHR was also inversely related to BD in the unadjusted analysis, the relationship no longer exists after controlling for BMI.
There are very few studies on the metabolic parameters in drug-naive bipolar patients in comparison with healthy controls. Guha et al. 15 reported higher fasting glucose and insulin in drug naive patients as compared with controls. In line with this finding, we observed that BD polygenic score are possibly associated with FG and INS, after controlling for BMI. We do not observe evidence of polygenic association of dyslipidemia with BD; on the contrary, there appeared to be an inverse relationship with LDL. This result could be confounded by BMI, but studies have found lower cholesterol level in bipolar patients 51, 52 . There is also evidence of a correlation between low cholesterol levels and suicide risks 53 . The underlying mechanism remains elusive, but it has been suggested that low cholesterol may be associated with decreased lipid microviscosity in neural membranes and reduced exposure of serotonin receptors on membrane surface. Serotonergic dysfunction may in turn contribute to suicidality 54 .
Taken together, we found evidence of genetic predisposition to the development of glucose metabolism abnormalities, DM and CAD in both schizophrenia and BD patients.
Schizophrenia patients are also genetically susceptible to developing central obesity. On the other hand, we observed an inverse relationship between polygenic scores of BMI with both schizophrenia and BD. There is no evidence of polygenic associations with dyslipidemia, but some preliminary evidence to the contrary.
14 Our findings call for an increased awareness and better monitoring and management of CVD risks in schizophrenia and BD patients. Given that these patients are at increased CVD risks independent of medication side-effects, proper surveillance and management of cardiovascular risk factors may be required even in patients who are taking drugs with less metabolic side-effects or low-dose medications. In addition, our findings suggested that the measurement of WHR (instead of BMI alone) might be useful in screening for metabolic risks.
There are a few limitations to our study. Our analyses are based on large-scale GWAS meta-analyses results, but most studies are done in Caucasians. It is worthwhile to extend the study to other ethnic groups. For analyses using paired summary results, we were unable to control for other clinical factors, for instance adjusting for WHR when studying CAD risks. As 
